Amazing effort by Alderwood at last week's charity bake sale for Action Duchenne- we raised £155! Thank you so much to every one who baked as …
Alderwood Recruitment hold bake sale for Action DuchenneRead More
Delay in access to Exondys 51
Last week, at the European Medicine’s Agency (EMA) the Committee for Medicinal Products for Human Use (CHMP) held a hearing …
Please opt in
GDPRIn order to continue our exceptional work we need your consent in line with the new GDPR rules. We need to receive your …
Capricor Announces Initiation of HOPE-2 Clinical Trial Of CAP-1002 for Duchenne Muscular Dystrophy
Capricor Therapeutics has announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Centre. The trial will test the safety …
Catabasis present new data showing significantly slowed Duchenne disease progression
Yesterday Catabasis reported new positive magnetic resonance efficacy results showing slowed disease progression in boys with Duchenne in the MoveDMD …
Catabasis present new data showing significantly slowed Duchenne disease progressionRead More
Daiichi Sankyo announce results of Phase 1/2 clinical trial
Daiichi Sankyo have announced the top-line results of the Phase 1/2 clinical trial in Japan of DS-5141 which Daiichi Sankyo is jointly developing with …
Daiichi Sankyo announce results of Phase 1/2 clinical trialRead More
Thank You – An announcement on the Early Access to Medicines Scheme for Raxone
We are delighted to announce that the MHRA have decided to maintain a positive opinion on the Early Access to Medicines Scheme for Raxone to treat …
Thank You – An announcement on the Early Access to Medicines Scheme for RaxoneRead More
Summit Presents New 24-Week Analyses from PhaseOut DMD trial
Data show correlation between decrease in muscle damage and reduction in muscle inflammation in patients treated with ezutromid Summit Therapeutics …
Summit Presents New 24-Week Analyses from PhaseOut DMD trialRead More
Capricor announces repeat dosing of CAP-1002 increases exercise performance in Duchenne mouse
Capricor Therapeutics today announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an increase …
Early data shows Eteplirsen tolerated safely in young infant with Duchenne
Muscular Dystrophy News Today report in their article that 'Exondys 51' ('Eteplirsen' in the UK), was according to preliminary data, safe and well …
Early data shows Eteplirsen tolerated safely in young infant with DuchenneRead More
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
"We believe the early improvements seen in muscle health in the interim data from PhaseOut DMD indicate ezutromid is reducing DMD disease severity. In …
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical TrialRead More
Solid address Duchenne community with update on IGNITE DMD Clinical Trial
Solid Biosciences have written to the Duchenne community to provide an update on their IGNITE DMD clinical trial. Below is a transcript of this letter …
Solid address Duchenne community with update on IGNITE DMD Clinical TrialRead More
